Pfizer/Bristol finalize metabolics development deal
Executive Summary
Pfizer and Bristol-Myers Squibb finalize agreement to research, develop and commercialize DGAT-1 inhibitors. Companies announced deal to collaborate on the DGAT-1 discovery program, which includes advanced pre-clinical compounds with potential applications for treatment of metabolic disorders like obesity and diabetes, in April (1"The Pink Sheet" April 30, 2007, p. 4). Pfizer will be responsible for all research and early-stage development, and the companies will jointly conduct Phase III development and commercialization. The two firms also have a separate deal to develop and market the Factor Xa inhibitor apixaban. Initial filing for apixaban, for venous thromboembolism, is expected in the second half of 2009...
You may also be interested in...
Bristol’s Pfizer, AstraZeneca Deals Could Add Up To $2 Billion To R&D Budget
Bristol-Myers Squibb's partnerships with AstraZeneca and Pfizer to develop several late-stage compounds may provide the company with $2 billion to support its research and development initiatives, the firm said
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.